Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (181-190 of 205) with videos related to

Pageof 21
Sort By:
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Pageof 21

Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
NPJ Precision Oncology|June 7, 2018
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumorChristopher Alvarez-Breckenridge, Julie J Miller, Naema Nayyar, et al.
The Lancet. Oncology|September 8, 2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyD Ross Camidge, Yung-Jue Bang, Eunice L Kwak, et al.
Cancer Discovery|April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung CancerSatoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery|August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung CancerAnna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Pageof 21